1. A milder form of NSRP1-associated neurodevelopmental disorder, caused by a missense variant in the nuclear localization signal.
- Author
-
Neuens S, Kausar M, Kang SK, Soblet J, Van Dooren S, Olsen C, Janssen T, Caljon B, Jun CD, Smits G, Coppens S, and Vilain C
- Subjects
- Adolescent, Female, Humans, HEK293 Cells, Intellectual Disability genetics, Intellectual Disability pathology, Phenotype, RNA-Binding Proteins genetics, Child, Preschool, Child, Mutation, Missense genetics, Neurodevelopmental Disorders genetics, Neurodevelopmental Disorders pathology, Neurodevelopmental Disorders diagnosis, Nuclear Localization Signals genetics
- Abstract
Nuclear Speckle Splicing Regulator Protein 1 (NSRP1) is a splice factor found in nuclear speckles, which are small membrane-free organelles implicated in epigenetic regulation, chromatin organization, DNA repair, and RNA modification. Bi-allelic loss-of-function variants in NSRP1 have recently been identified in patients suffering from a severe neurodevelopmental disorder, presenting with neurodevelopmental delay, epilepsy, microcephaly, hypotonia, and spastic cerebral palsy. Described patients acquired neither independent walking nor speech and often showed anomalies on cerebral MRI. Here we describe the case of a 14-year-old girl with motor and language delay as well as intellectual disability, who presents an ataxic gait but walks without assistance and speaks in short sentences. Whole-genome sequencing revealed the compound heterozygous NSRP1 variants c.114 + 2T > G and c.1595T > A (p.Val532Glu). Functional validation using HEK293T cells transfected with either wild-type or mutated GFP-tagged Nsrp1 suggests that the Val532Glu variant interferes with the function of the nuclear localization signal, and leads to mislocalization of NSRP1 in the cytosol, thus confirming the pathogenicity of the observed variant. This case helps to expand the phenotypic and genetic spectrum associated with pathogenic NSRP1 variants and indicates that this diagnosis should also be suspected in patients with milder phenotypes., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF